published meta-analysis   sensitivity analysis   studies

remdesivir in COVID-19 severe or critically - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsCAP-China (Wang et al.), 2020 1.10 [0.49; 2.45] 1.10[0.49; 2.45]CAP-China (Wang et al.), 202010%236lownot evaluable clinical improvementdetailed resultsCAP-China (Wang et al.), 2020 1.23 [0.87; 1.74] 1.23[0.87; 1.74]CAP-China (Wang et al.), 202010%237lownot evaluable clinical improvement (14-day)detailed resultsCAP-China (Wang et al.), 2020 1.21 [0.64; 2.28] 1.21[0.64; 2.28]CAP-China (Wang et al.), 202010%236lownot evaluable clinical improvement (28-day)detailed resultsCAP-China (Wang et al.), 2020 1.37 [0.79; 2.39] 1.37[0.79; 2.39]CAP-China (Wang et al.), 202010%236lownot evaluable clinical improvement (7-day)detailed resultsCAP-China (Wang et al.), 2020 0.99 [0.18; 5.51] 0.99[0.18; 5.51]CAP-China (Wang et al.), 202010%236lownot evaluable clinical improvement (time to event analysis only)detailed resultsCAP-China (Wang et al.), 2020 1.23 [0.87; 1.74] 1.23[0.87; 1.74]CAP-China (Wang et al.), 202010%237lownot evaluable AE leading to drug discontinuationdetailed resultsCAP-China (Wang et al.), 2020 2.43 [0.79; 7.45] 2.43[0.79; 7.45]CAP-China (Wang et al.), 202010%233lownot evaluable serious adverse eventsdetailed resultsCAP-China (Wang et al.), 2020 0.64 [0.33; 1.23] 0.64[0.33; 1.23]CAP-China (Wang et al.), 202010%233lownot evaluable deep vein thrombosisdetailed resultsCAP-China (Wang et al.), 2020 0.50 [0.03; 8.10] 0.50[0.03; 8.10]CAP-China (Wang et al.), 202010%233lownot evaluable elevated liver enzymesdetailed resultsCAP-China (Wang et al.), 2020 0.36 [0.13; 1.01] 0.36[0.13; 1.01]CAP-China (Wang et al.), 202010%233lownot evaluable hyperbilirubinemiadetailed resultsCAP-China (Wang et al.), 2020 1.09 [0.42; 2.79] 1.09[0.42; 2.79]CAP-China (Wang et al.), 202010%233lownot evaluable pulmonary embolismdetailed resultsCAP-China (Wang et al.), 2020 0.50 [0.03; 8.10] 0.50[0.03; 8.10]CAP-China (Wang et al.), 202010%233lownot evaluable renal impairmentdetailed resultsCAP-China (Wang et al.), 2020 1.01 [0.03; 30.33] 1.01[0.03; 30.33]CAP-China (Wang et al.), 202010%233lownot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2021-01-19 06:16 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 91 - treatments: 510 - roots T: 290